Symptomatic toxicities experienced during anticancer treatment: Agreement between patient and physician reporting in three randomized trials

Journal of Clinical Oncology

Volumn 33, Issue 8, 2015, Pages 910-915

  Di Maio, Massimo ^a   Gallo, Ciro ^b   Leighl, Natasha B ^h   Piccirillo, Maria Carmela ^a   Daniele, Gennaro ^a   Nuzzo, Francesco ^a   Gridelli, Cesare ^d   Gebbia, Vittorio ^e   Ciardiello, Fortunato ^b   De Placido, Sabino ^c   Ceribelli, Anna ^f   Favaretto, Adolfo G ^g   De Matteis, Andrea ^a   Feld, Ronald ^h   Butts, Charles ⁱ   Bryce, Jane ^a   Signoriello, Simona ^b   Morabito, Alessandro ^a   Rocco, Gaetano ^a   Perrone, Francesco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Second University   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d S G MOSCATI HOSPITAL   (Italy)

^e LA MADDALENA CANCER CENTER   (Italy)

^f REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^g VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^h PRINCESS MARGARET HOSPITAL   (Canada)

ⁱ CROSS CANCER INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ERLOTINIB; FLUOROURACIL; GEMCITABINE; METHOTREXATE; ROFECOXIB; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANOREXIA; ARTICLE; BREAST CANCER; CONSTIPATION; DIARRHEA; DOCTOR PATIENT RELATION; FEMALE; HAIR LOSS; HUMAN; INCIDENT REPORT; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYMPTOM; VOMITING; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICALLY INDUCED; CONTROLLED STUDY; EUROPE; HYPOTRICHOSIS; LUNG NEOPLASMS; MIDDLE AGED; PATIENT PARTICIPATION; PHYSICIAN; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANOREXIA; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CONSTIPATION; DIARRHEA; EUROPE; FEMALE; HUMANS; HYPOTRICHOSIS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; PATIENT PARTICIPATION; PHYSICIANS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME; VOMITING;

EID: 84921904953     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.9334     Document Type: Article

References (21)

1. Basch E, Bennett A, Pietanza MC: Use of patient-reported outcomes to improve the predictive accuracy of clinician-reported adverse events. J Natl Cancer Inst 103:1808-1810, 2011
2. Petersen MA, Larsen H, Pedersen L, et al: Assessing health-related quality of life in palliative care: Comparing patient and physician assessments. Eur J Cancer 42:1159-1166, 2006
3. Fromme EK, Eilers KM, Mori M, et al: How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol 22:3485-3490, 2004
4. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines: American Society of Clinical Oncology. J Clin Oncol 14:671-679, 1996
5. Haynes RB, Devereaux PJ, Guyatt GH: Physicians' and patients' choices in evidence based practice. BMJ 324:1350, 2002
6. Basch E: New frontiers in patient-reported outcomes: Adverse event reporting, comparative effectiveness, and quality assessment. Annu Rev Med 65:307-317, 2014
7. Nuzzo F, Morabito A, De Maio E, et al: Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: Safety data from the multicentre phase 3 randomised ELDA trial. Crit Rev Oncol Hematol 66:171-180, 2008
8. Gridelli C, Gallo C, Ceribelli A, et al: Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: The GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol 8:500-512, 2007
9. Gridelli C, Ciardiello F, Gallo C, et al: First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: The TORCH randomized trial. J Clin Oncol 30:3002-3011, 2012
10. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
11. Bergman B, Aaronson NK, Ahmedzai S, et al: The EORTC QLQ-LC13: A modular supplement to the EORTC Core Quality of Life Questionnaire (QLQC30) for use in lung cancer clinical trials-EORTC Study Group on Quality of Life. Eur J Cancer 30A:635-642, 1994
12. Sprangers MA, Groenvold M, Arraras JI, et al: The European Organisation for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: First results from a three-country field study. J Clin Oncol 14:2756-2768, 1996
13. Cohen J: A coefficient of agreement for nominal scales. Educ Psychol Meas 20:37-46, 1960
14. Fleiss JL: Statistical Methods for Rates and Proportions (ed 2). New York, NY, John Wiley, 1981, pp 38-46
15. Basch E, Iasonos A, McDonough T, et al: Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: Results of a questionnaire-based study. Lancet Oncol 7:903-909, 2006
16. Grossman SA, Sheidler VR, Swedeen K, et al: Correlation of patient and caregiver ratings of cancer pain. J Pain Symptom Manage 6:53-57, 1991
17. Cirillo M, Venturini M, Ciccarelli L, et al: Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: Results of a comparison based on patient's self-reported questionnaire. Ann Oncol 20:1929-1935, 2009
18. Gravis G, Marino P, Joly F, et al: Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15). Eur J Cancer 50:953-962, 2014
19. Basch EM, Reeve BB, Mitchell SA, et al: Electronic toxicity monitoring and patient-reported outcomes. Cancer J 17:231-234, 2011
20. Bruner DW, Hanisch LJ, Reeve BB, et al: Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Transl Behav Med 1:110-122, 2011
21. Trotti A, Colevas AD, Setser A, et al: Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol 25:5121-5127, 2007